The expansion will feature added capabilities for formulation development via the upgrade of drug product development laboratories and the addition of Gerteis roller compaction equipment for dry granulation processing.
Lonza announced on Nov. 18, 2020 that it is expanding its highly potent API (HPAPI) drug product development and manufacturing capabilities at its Tampa, FL site.
According to a company press release, the expansion will feature added capabilities for formulation development via the upgrade of drug product development laboratories and the addition of Gerteis roller compaction equipment for dry granulation processing.
"Our customers look to Lonza to meet their challenge of accelerating timelines to clinic and market. In response, we strive for seamless service provision across our drug substance and drug product development and manufacturing network,” said Christian Dowdeswell, vice-president and global head of Commercial Development, Small Molecules, Lonza, in the press release. “These new investments ensure that we have capabilities that meet our customers' needs and standardizes state-of-the-art continuous dry granulation across Lonza's solid oral dose manufacturing network. This gives us more flexibility in development as well as facilitating more rapid scale-up."
"The ability to safely and efficiently handle HPAPI is increasingly critical to effectively partner with our customers, especially those focused on cancer therapies,” added Robert Beland, Managing Director, Lonza Tampa, in the press release. “The new roller compactor complements the capabilities of both the Tampa site and our overall network for product development and manufacturing based on HPAPI."
Source: Lonza
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.